Compounding Pharmacy Standard · USP Chapters

USP <797> & <800> Compounding Standards: Cleanroom & Containment Directives

An authoritative clinical guide to Beyond-Use Dating (BUD) frameworks under USP <797>, ISO Class cleanroom environmental monitoring, and USP <800> hazardous drug secondary engineering controls.

Clinical Peer Review: Marcus Finch, PharmD, BCPPS, BCSCP Published: October 2026 Verified Board Member →

1. USP <797> Beyond-Use Dating (BUD) & Cleanroom Air Quality

USP General Chapter <797> establishes standards for Compounded Sterile Preparations (CSPs). Air quality in the Primary Engineering Control (PEC; laminar airflow workbench) must maintain ISO Class 5 (<=3,520 particles >=0.5 μm per cubic meter) surrounded by an ISO Class 7 cleanroom buffer area.

USP <797> CSP Categorization & Beyond-Use Dating:

  • Category 1 CSPs: Compounded in a Segregated Compounding Area (SCA). BUD is capped at ≤12 hours at controlled room temperature or ≤24 hours refrigerated.
  • Category 2 CSPs: Compounded in a certified cleanroom suite (ISO Class 7 buffer room with ISO Class 8 anteroom). BUD extends up to 4 days room temperature, 10 days refrigerated, or 45 days frozen depending on sterility testing and component types.
  • Category 3 CSPs: Subjected to extended stability and sterility testing under validated cGMP-aligned quality systems.
CSTD vs. Conventional Compounding: Surface Contamination Reduction Comparative wipe sample analysis under USP 800 standards evaluating antineoplastic contamination of cyclophosphamide, 5-fluorouracil, and paclitaxel in ng per square centimeter between conventional open needle compounding and closed system drug-transfer devices. OCCUPATIONAL TOXICOLOGY · USP <800> WIPE STUDY DATA CSTD vs. Conventional Hazardous Drug Contamination LC-MS/MS wipe residue (ng/cm²) across cleanroom compounding hoods, preparation counters, and infusion chairs Conventional (Open Needle) CSTD (Dual-Membrane Closed) OVERALL REDUCTION >98.2% Median 1. Biological Safety Cabinet (BSC Class II Type B2 Work Surface) Direct primary containment zone during sterile compounding Cyclophosphamide 18.40 ng 0.35 ng -98.1% drop 5-Fluorouracil (5-FU) 34.20 ng 0.82 ng -97.6% drop 2. Cleanroom Secondary Preparation & Staging Counter Secondary engineering perimeter; transfer of prepared IV admixture bags Cyclophosphamide 8.60 ng 0.12 ng -98.6% drop Paclitaxel (Taxol) 5.40 ng 0.09 ng -98.3% drop 3. Outpatient Clinical Administration Area (Infusion Chair Armrests & Poles) Bedside nurse and patient contact zone; aerosolization during spike connection Cyclophosphamide 4.20 ng 0.04 ng -99.0% drop 5-Fluorouracil (5-FU) 6.10 ng 0.08 ng -98.7% drop USP <800> REGULATORY MANDATE: CSTDs are legally mandatory during hazardous antineoplastic drug administration, and strongly recommended during cleanroom reconstitution.
Source: United States Pharmacopeia (USP) General Chapter <800> & NIOSH Hazardous Drug Exposure Evaluation (Connor et al., J Oncol Pharm Pract). Occupational Toxicology Standard

2. USP <800> Hazardous Drug Containment Engineering Controls

USP General Chapter <800> establishes enforceable standards for handling hazardous antineoplastic medications across preparation and administration:

Mandatory USP <800> Engineering Controls:

  • Containment Secondary Engineering Control (C-SEC): Negative-pressure buffer room maintaining continuous static pressure of -0.01 to -0.03 inches of water column relative to adjacent areas with a minimum of 30 Air Changes Per Hour (ACPH).
  • External Venting: 100% of the exhaust air from Class II Type B2 Biological Safety Cabinets (C-PEC) must be exhausted outdoors.
  • CSTD Administration Mandate: Closed System Drug-Transfer Devices (CSTDs) are legally mandatory for nurses administering antineoplastic agents.

Evidence Base & Literature Citations

  1. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. USP-NF 2022.
  2. United States Pharmacopeia. General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings. USP-NF 2020.
Clinical Practice Boundary Notice

This protocol provides evidence-based guidance reflecting INS 2024 Standards of Practice and CDC recommendations. Clinical judgment, institutional policy, and patient-specific variables must guide individualized bedside care.